Cargando…

1583P COVID-19 related risk in patients enrolled in early-phase clinical trials

Detalles Bibliográficos
Autores principales:	D'Amico, P., Trillo, P., Morganti, S., Corti, C., Vivanet, G., Crimini, E., Ascione, L., Tarantino, P., Antonarelli, G., Locatelli, M., Esposito, A., Belli, C., Curigliano, G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Society for Medical Oncology. Published by Elsevier Ltd. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454342/ http://dx.doi.org/10.1016/j.annonc.2021.08.1576

Ejemplares similares

Safety of COVID-19 mRNA Vaccines in Patients with Cancer Enrolled in Early-Phase Clinical Trials
por: Trillo Aliaga, Pamela, et al.
Publicado: (2021)

Challenges and Obstacles in Applying Therapeutical Indications Formulated in Molecular Tumor Boards
por: Crimini, Edoardo, et al.
Publicado: (2022)

Therapeutic cancer vaccines revamping: technology advancements and pitfalls
por: Antonarelli, G., et al.
Publicado: (2021)

Targeting Cellular Components of the Tumor Microenvironment in Solid Malignancies
por: Belli, Carmen, et al.
Publicado: (2022)

Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure
por: Antonarelli, G., et al.
Publicado: (2023)

Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies
por: Antonarelli, Gabriele, et al.
Publicado: (2021)

Loss of HER2 in breast cancer: biological mechanisms and technical pitfalls
por: Morganti, Stefania, et al.
Publicado: (2022)

Reglage des "Gates Control" U 1583
por: Hoh, R
Publicado: (1976)

SARS-CoV-2 vaccines for cancer patients: a call to action
por: Corti, Chiara, et al.
Publicado: (2021)

PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-Negative
por: Ascione, Liliana, et al.
Publicado: (2022)

Predicting Response to Antibody Drug Conjugates: A Focus on Antigens’ Targetability
por: Ascione, Liliana, et al.
Publicado: (2023)

Seroconversion rate after vaccination against COVID-19 in patients with cancer—a systematic review
por: Corti, C., et al.
Publicado: (2022)

Opportunities and challenges of implementing Pharmacogenomics in cancer drug development
por: Tarantino, Paolo, et al.
Publicado: (2019)

Repurposing of Diagnostic Whole Exome Sequencing Data of 1,583 Individuals for Clinical Pharmacogenetics
por: van der Lee, Maaike, et al.
Publicado: (2019)

P1583: TRANSFUSIONS IN AUTOIMMUNE HEMOLYTIC ANEMIA: FREQUENCY AND CLINICAL SIGNIFICANCE OF ALLOIMMUNIZATION
por: Versino, Francesco, et al.
Publicado: (2023)

Targeting HER2 in breast cancer: new drugs and paradigms on the horizon
por: Tarantino, Paolo, et al.
Publicado: (2021)

El debate sobre la guerra chichimeca, 1531-1583 : derecho y política en la Nueva España /
por: Carrillo Cázares, Alberto
Publicado: (2000)

Immobilization of Lipase from Penicillium sp. Section Gracilenta (CBMAI 1583) on Different Hydrophobic Supports: Modulation of Functional Properties
por: Turati, Daniela F. M., et al.
Publicado: (2017)

P1583: EVALUATION OF THE KNOWLEDGE OF HEMATOLOGISTS ABOUT THE MANAGEMENT OF INFECTIOUS COMPLICATIONS IN HEMATOLOGIC PATIENTS
por: Guaraná, M., et al.
Publicado: (2022)

La administración del Colegio de San Pedro y San Pablo (1583-1584)
por: Mijares, Ivonne
Publicado: (1986)

Targeting HER3 for cancer treatment: a new horizon for an old target
por: Uliano, J., et al.
Publicado: (2023)

How I treat HER2-positive early breast cancer: how long adjuvant trastuzumab is needed?
por: Morganti, S., et al.
Publicado: (2022)

Antibody–Drug Conjugates for the Treatment of Breast Cancer
por: Corti, Chiara, et al.
Publicado: (2021)

Cardiac effects of the c.1583 C→G LMNA mutation in two families with Emery-Dreifuss muscular dystrophy
por: ZHANG, LI, et al.
Publicado: (2015)

HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer
por: Venetis, Konstantinos, et al.
Publicado: (2022)

Commentary: SARS-CoV-2 vaccines and cancer patients
por: Corti, C., et al.
Publicado: (2021)

Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trials
por: Hyman, David M., et al.
Publicado: (2015)

Sustained Improvement in the Management of Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocation: Where Are We Running?
por: Spitaleri, Gianluca, et al.
Publicado: (2023)

1583. Optimal timing of antiretroviral therapy initiation in AIDS-associated Toxoplasma encephalitis: a prospective observational multicenter study in China
por: Chen, yaokai, et al.
Publicado: (2023)

Conducting phase 1 cancer clinical trials during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–related disease pandemic
por: Tarantino, Paolo, et al.
Publicado: (2020)

Reduction of microalbuminuria in patients with type 2 diabetes: the Shiga Microalbuminuria Reduction Trial (SMART). Diabetes Care 2007;30:1581–1583
Publicado: (2013)

1583. The Utility of the Immunodeficiency Scoring Index (ISI) to Predict Outcomes of Coronavirus (HCoV) Infections in Hematopietic Cell Transplant (HCT) Recipients
por: Khawaja, Fareed, et al.
Publicado: (2018)

Tumor Infiltrating Lymphocytes across Breast Cancer Subtypes: Current Issues for Biomarker Assessment
por: Valenza, Carmine, et al.
Publicado: (2023)

Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials
por: Groisberg, Roman, et al.
Publicado: (2017)

1583. Eight Years of Sustained Potency and Activity of Oritavancin against Gram-Positive Isolates Causing Bacteremia and Endocarditis in the USA, Including Enterococcal Infections Requiring an Optimized Dosing Strategy for Daptomycin
por: Carvalhaes, Cecilia G, et al.
Publicado: (2019)

Immunotherapy for early triple negative breast cancer: research agenda for the next decade
por: Tarantino, Paolo, et al.
Publicado: (2022)

Factors associated with enrolment in clinical trials among women with early-stage breast cancer
por: Presti, D., et al.
Publicado: (2022)

Targeting Post-Translational Modifications to Improve Combinatorial Therapies in Breast Cancer: The Role of Fucosylation
por: Antonarelli, Gabriele, et al.
Publicado: (2023)

1583. In Vitro Activity of Imipenem/Relebactam against Klebsiella pneumoniae and Pseudomonas aeruginosa from Patients in ICUs in the Asia/Pacific region – SMART 2015-2018
por: Lob, Sibylle, et al.
Publicado: (2020)

Tumour dormancy and clinical implications in breast cancer
por: Gelao, L, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_uks7reihprunck0bhaf17qdaor